These tumor-intrinsic features may inform rational selection and optimization of first-line and consolidative therapy.<h4>Significance</h4>In a large-scale, contemporary cohort of patients with advanced ALK-positive NSCLC, we evaluated molecular characteristics and their impact on acquired resistance mutations and clinical outcomes. This evidence concerns the gene ALK and non-small cell lung carcinoma.